Cortechs.ai Expands Its AI Neuroimaging Tools With ZepMed Acquisition

Cortechs.ai Acquires ZepMed to Enhance AI-Powered Neuroimaging Capabilities

Cortechs.ai, a recognized leader in artificial intelligence-driven neuroimaging software, has taken a significant step forward with its recent acquisition of intellectual property from ZepMed, LLC. This acquisition not only includes the cutting-edge patented CT imaging technologies but also ZepMed's flagship product, NeuroAlign CT™. By integrating these advanced technologies, Cortechs.ai aims to strengthen its position at the forefront of radiological innovation while broadening its portfolio of solutions designed for healthcare professionals globally.

Kyle Frye, CEO of Cortechs.ai, emphasized the strategic nature of this acquisition, stating, "With this acquisition, we're not just expanding our portfolio, we're building on ZepMed's foundation to elevate development and deliver even more powerful tools to our users." This move marks an important milestone for Cortechs.ai as it seeks to enhance the solutions trusted by healthcare professionals around the world.

ZepMed is well-known for its pioneering contributions to CT imaging. The company's NeuroAlign CT™, which has earned Class II FDA clearance, automates the segmentation, alignment, and reformatting of head CT scans. This innovative technology significantly enhances diagnostic accuracy and expedites radiology workflows, enabling clinicians to detect subtle changes in brain anatomy with increased speed and confidence.

Douglas Bates, MD, a co-founder of ZepMed, expressed his pride in what the team built with NeuroAlign, stating, "We are excited to see it reach its full potential in the hands of Cortechs.ai." He noted their enthusiasm for Cortechs.ai's development team, which will be instrumental in enhancing the user experience and adding features that will benefit a greater number of clinicians and patients worldwide.

Daniel Livschutz, the Chairman of the Board for Cortechs.ai and Founding Partner of VILAS Ventures, reiterated the positive implications of this acquisition. He stated, "This ownership strengthens our commitment to delivering AI-powered diagnostic solutions that span both neuroimaging and radiology. With the integration of ZepMed's innovations, we're not just adding capabilities, we're architecting a continuum of care that spans surveillance, diagnosis, and risk." This strategic positioning aims to move beyond existing silos into a multimodal ecosystem, thereby serving patients, clinicians, and payers more effectively.

The integration of ZepMed's technology under Cortechs.ai catalyzes innovation and broadens its neuroimaging portfolio, which reinforces its leadership in the AI-powered radiology space. The ultimate goal is to improve patient outcomes via precision diagnostics.

About Cortechs.ai

Cortechs.ai focuses on revolutionizing disease screening and early detection through cutting-edge technologies in medical imaging. The company develops advanced medical device software tailored for quantifying and tracking neurodegenerative diseases while also assisting in clinically significant cancer detection. With FDA-cleared products aimed at diagnosing and following neurodegenerative and traumatic brain conditions, as well as prostate cancer, Cortechs.ai is committed to providing an effective and cost-efficient means for radiologists, neurologists, oncologists, and researchers worldwide to assess brain abnormalities.

For further details, please visit Cortechs.ai and check out their updates on Twitter, LinkedIn, and Facebook.

About ZepMed

ZepMed is a pioneer in medical imaging software, particularly known for its advanced CT solutions that boost radiology interpretation speed and accuracy. Its flagship software, NeuroAlign CT™, is FDA-cleared and patented. ZepMed's technology has been recognized for its transformative impact on radiology workflows and enhancing diagnostic confidence across various clinical settings.